Peptide Comparison
Gonadorelin vs hCG
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Recommended pick
hCG has both the pharmacology and the published human data for maintaining testicular function during exogenous testosterone. Gonadorelin, as it is most often described in community protocols, has neither. Gonadorelin is GnRH itself, cleared in roughly 10 to 40 minutes, and its approved use delivers 5 microgram pulses every 90 minutes by pump, because the pituitary responds to pulsatile GnRH and downregulates under sustained exposure. hCG has a half-life near 24 to 33 hours and acts directly at the LH receptor, below the pituitary entirely. Twice-weekly subcutaneous gonadorelin reproduces neither the approved pulsatile regimen nor the sustained receptor occupancy hCG provides. Consult a qualified clinician before any human use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
Both are approved products and both raise testosterone, at different points on the axis. Gonadorelin acts on GnRH receptors on the pituitary and depends on the pituitary responding. hCG acts on LH receptors on Leydig cells and does not. Their half-lives differ by roughly two orders of magnitude, which is the reason the two cannot be dosed on the same schedule.
Which one to pick
Pick Gonadorelin if
- Pulsatile pump administration is available, which is the route the approval covers
- Diagnostic assessment of pituitary responsiveness is the purpose
- A short-acting agent is specifically required
Pick hCG if
- Testicular preservation during exogenous testosterone is the goal, where Hsieh 2013 reported low-dose hCG maintaining semen parameters
- Pituitary output is absent or unreliable
- A dosing interval measured in days rather than minutes is required
Avoid both if
- There is suspected or confirmed androgen-dependent neoplasia
- The context is pediatric, where precocious puberty is a documented risk
- The patient is female and pregnant or planning pregnancy, where hCG carries documented ovarian hyperstimulation and thromboembolism risk
Common confusions
- 'Gonadorelin is a safer hCG'. They are not substitutes. hCG replaces the pituitary's signal. Gonadorelin asks the pituitary for it. Where the pituitary is the problem, gonadorelin has nothing to act on.
- 'Twice-weekly gonadorelin maintains testicular function'. No published trial supports that schedule. A peptide cleared in 10 to 40 minutes gives a few hours of exposure per week on that pattern, and sustained rather than pulsatile GnRH exposure downregulates the receptor, which is the mechanism GnRH agonists use to suppress the axis in prostate cancer treatment.
- 'Gonadorelin avoids desensitization because it is identical to natural GnRH'. Being identical to the endogenous hormone is precisely what makes the schedule matter. The catalog records pituitary desensitization under continuous infusion for this compound.
Side-by-side
| Gonadorelin | hCG | |
|---|---|---|
| Class | GnRH decapeptide (FDA-approved) | Placental glycoprotein hormone (FDA-approved); LH-receptor agonist |
| Drug class | Sexual-Health | Sexual-Health |
| Mechanism | GnRH receptor agonist on pituitary; pulsatile stimulation of LH/FSH | LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation |
| Route | SC / IV | IM / SC |
| Half-life | ~10-40 min | ~33 hrs (urine-derived); ~24 hrs (recombinant) |
| Dosage (research) | 100 mcg SC 2x weekly (TRT adjunct starting dose, may go up to 300 mcg per dose 3x weekly per community protocols); 5 mcg IV pulses every 90 minutes (Lutrepulse pump for infertility) | Female ovulation trigger: 5,000-10,000 USP units IM single dose 1 day after final gonadotropin (FDA Pregnyl/Novarel label). Male off-label: 250 IU SC 2x weekly TRT adjunct (Bhasin Endocrine Society 2018 starting dose, may go higher per response); 1,000 IU IM 2x weekly HPG restart (Crisler protocol starting dose) |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 268 indexed | 274 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Pituitary desensitization with continuous infusion | Ovarian hyperstimulation syndrome (OHSS); thromboembolism; gynecomastia (males at high dose); arterial-thrombosis case reports; contraindicated in suspected/confirmed prostate or other androgen-dependent neoplasia; precocious puberty risk in pediatric use |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Gonadorelin or hCG?
hCG has both the pharmacology and the published human data for maintaining testicular function during exogenous testosterone. Gonadorelin, as it is most often described in community protocols, has neither. Gonadorelin is GnRH itself, cleared in roughly 10 to 40 minutes, and its approved use delivers 5 microgram pulses every 90 minutes by pump, because the pituitary responds to pulsatile GnRH and downregulates under sustained exposure. hCG has a half-life near 24 to 33 hours and acts directly at the LH receptor, below the pituitary entirely. Twice-weekly subcutaneous gonadorelin reproduces neither the approved pulsatile regimen nor the sustained receptor occupancy hCG provides. Consult a qualified clinician before any human use.
What is the difference between Gonadorelin and hCG?
Gonadorelin is classed as GnRH decapeptide (FDA-approved); hCG is classed as Placental glycoprotein hormone (FDA-approved); LH-receptor agonist. Reported mechanism: Gonadorelin, GnRH receptor agonist on pituitary; pulsatile stimulation of LH/FSH; hCG, LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation. Reported half-life: Gonadorelin, ~10-40 min; hCG, ~33 hrs (urine-derived); ~24 hrs (recombinant). Routes in published studies: Gonadorelin, SC / IV; hCG, IM / SC.
Which has stronger evidence, Gonadorelin or hCG?
Gonadorelin and hCG sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Gonadorelin is graded FDA-Approved, with 9 cited sources on its reference page and 268 indexed studies. hCG is graded FDA-Approved, with 23 cited sources on its reference page and 274 indexed studies.
Which is more accessible, Gonadorelin or hCG?
Both Gonadorelin and hCG are FDA-approved drugs. Catalog status: Gonadorelin, Prescription; hCG, Prescription.
Are Gonadorelin and hCG ever combined?
Gonadorelin and hCG appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…